Greenwich Stock Executives

GLSI -  USA Stock  

USD 8.66  0.24  2.70%

Examination of Greenwich Lifesciences management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Greenwich Lifesciences future performance.
Please check Risk vs Return Analysis.
Symbol  GLSI
Name  Greenwich Lifesciences
TypeStock
Country   United States
Exchange  NASDAQ

Information on Greenwich Lifesciences Leadership is currently not available.

If you believe this information is not accurate please let us know and we will check it out.

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Greenwich Lifesciences Management Team Effectiveness

Greenwich Lifesciences has return on total asset (ROA) of (10.28) % which means that it has lost $10.28 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (16.78) %, meaning that it created substantial loss on money invested by shareholders. Greenwich Lifesciences management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Assets is estimated to decrease to -0.17. The current Return on Invested Capital is estimated to decrease to 7.81. Greenwich Lifesciences Assets Non Current are most likely to decrease significantly in the upcoming years. The last year's value of Assets Non Current was reported at 17,852.4. The current Goodwill and Intangible Assets is estimated to increase to about 14.2 K, while Total Assets are projected to decrease to roughly 22.4 M.

Greenwich Lifesciences Quarterly Total Assets

19.75 Million

Share
The current Issuance Purchase of Equity Shares is estimated to increase to about 3.2 M, while Weighted Average Shares is projected to decrease to roughly 10.4 M.

Greenwich Lifesciences Workforce Comparison

Greenwich Lifesciences is rated # 3 in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 312. Greenwich Lifesciences maintains roughly 3.0 in number of employees contributing less than 1% to stocks in Biotechnology industry.

Greenwich Lifesciences Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Greenwich Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Greenwich Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Greenwich Lifesciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Greenwich Lifesciences Benchmark Summation

The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Index of highest value over a specified period line plots maximum indexes of Greenwich Lifesciences price series.
.

About Greenwich Lifesciences Management Performance

The success or failure of an entity such as Greenwich Lifesciences often depends on how effective the management is. Greenwich Lifesciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Greenwich management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Greenwich management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Average Assets(0.16) (0.17) 
Return on Average Equity(0.16) (0.16) 
Return on Invested Capital 8.44  7.81 
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
The data published in Greenwich Lifesciences' official financial statements usually reflect Greenwich Lifesciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Greenwich Lifesciences. For example, before you start analyzing numbers published by Greenwich accountants, it's critical to develop an understanding of what Greenwich Lifesciences' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Greenwich Lifesciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Greenwich Lifesciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Greenwich Lifesciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Greenwich Lifesciences. Please utilize our Beneish M Score to check the likelihood of Greenwich Lifesciences' management to manipulate its earnings.
Please check Risk vs Return Analysis. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.